VivoSeq
Oncology

Angiosarcoma

23

Pipeline Programs↗

4

Active Trials↗

15

Companies Involved↗

Angiosarcoma is an emerging landscape with 23 programs across 15 companies. The most active players are Eastern Cooperative Oncology Group, AstraZeneca, Bayer. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

6/100

Mech. Concentration

15/100

Completion Rate

63/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Bayer logo

Bayer

2 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

61%

Small molecule

14 of 23 classified programs — the dominant modality here.

39%ALL OTHERSMonoclonal antibody522%Gene therapy29%Protein / enzyme14%Vaccine14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

25

clinical trials

Completed10 · 40%
Unknown status5 · 20%
Terminated4 · 16%
Recruiting3 · 12%
Withdrawn2 · 8%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT07007273·17 enrolled
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Recruiting·VVarun Monga, MBBS·Phase 2·NCT06898970·18 enrolled
The Phase II Study of Pembrolizumab Plus Lenvatinib in Patients With Unresectable Cutaneous Angiosarcoma
Recruiting·National Cancer Center, Japan·Phase 2·NCT06673628·38 enrolled
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Active, not recruiting·WWashington University School of Medicine·Phase 1/2·NCT03921008·20 enrolled
Bevacizumab in Treating Patients With Angiosarcoma
Completed·NNorthwestern University·Phase 2·NCT00288015·32 enrolled
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Completed·TTracon Pharmaceuticals Inc.·Phase 3·NCT02979899·128 enrolled
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
Completed·UUNICANCER·Phase 2·NCT00217607·30 enrolled
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Completed·NNorthwestern University·Phase 2·NCT02048722·31 enrolled
Propranolol in Angiosarcoma
Completed·TThe Netherlands Cancer Institute·Phase 2·NCT04518124·14 enrolled
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Completed·National Cancer Institute (NCI)·Phase 2·NCT01623869·16 enrolled
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Completed·FFox Chase Cancer Center·Phase 2·NCT01462630·29 enrolled
Cemiplimab for Secondary Angiosarcomas
Completed·RRadboud University Medical Center·Phase 2·NCT04873375·18 enrolled
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Completed·AAthenex, Inc.·Phase 2·NCT03544567·48 enrolled
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
Completed·CCentre Oscar Lambret·Phase 2·NCT01303497·70 enrolled
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03921073·5 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)